A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
Progression‐free survival (PFS) has been increasingly used as a primary endpoint for early clinical development. The aim of the present work was to develop a model where target lesion dynamics and risk for nontarget progression are jointly modeled for predicting PFS. The model was developed based on...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-03-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12499 |
id |
doaj-bb192ad3c4384059a862f04a9b70eecf |
---|---|
record_format |
Article |
spelling |
doaj-bb192ad3c4384059a862f04a9b70eecf2020-11-25T03:35:35ZengWileyCPT: Pharmacometrics & Systems Pharmacology2163-83062020-03-019317718410.1002/psp4.12499A New Method to Model and Predict Progression Free Survival Based on Tumor Growth DynamicsJiajie Yu0Nina Wang1Matts Kågedal2Department of Clinical PharmacologyGenentech Research and Early Development South San Francisco California USADepartment of Clinical PharmacologyGenentech Research and Early Development South San Francisco California USADepartment of Clinical PharmacologyGenentech Research and Early Development South San Francisco California USAProgression‐free survival (PFS) has been increasingly used as a primary endpoint for early clinical development. The aim of the present work was to develop a model where target lesion dynamics and risk for nontarget progression are jointly modeled for predicting PFS. The model was developed based on a pooled platinum‐resistant ovarian cancer dataset comprising four different treatments and a wide range of dose levels. The target lesion progression was derived from tumor growth dynamics based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The nontarget progression hazard was correlated to the first derivative of target lesion tumor size with respect to time. The PFS time was determined by the first occurring event, target lesion progression, or nontarget progression. The final joint model not only captured target lesion tumor growth dynamics but also predicted PFS well. A similar approach can potentially be used to predict PFS in future oncology studies.https://doi.org/10.1002/psp4.12499 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jiajie Yu Nina Wang Matts Kågedal |
spellingShingle |
Jiajie Yu Nina Wang Matts Kågedal A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics CPT: Pharmacometrics & Systems Pharmacology |
author_facet |
Jiajie Yu Nina Wang Matts Kågedal |
author_sort |
Jiajie Yu |
title |
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics |
title_short |
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics |
title_full |
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics |
title_fullStr |
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics |
title_full_unstemmed |
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics |
title_sort |
new method to model and predict progression free survival based on tumor growth dynamics |
publisher |
Wiley |
series |
CPT: Pharmacometrics & Systems Pharmacology |
issn |
2163-8306 |
publishDate |
2020-03-01 |
description |
Progression‐free survival (PFS) has been increasingly used as a primary endpoint for early clinical development. The aim of the present work was to develop a model where target lesion dynamics and risk for nontarget progression are jointly modeled for predicting PFS. The model was developed based on a pooled platinum‐resistant ovarian cancer dataset comprising four different treatments and a wide range of dose levels. The target lesion progression was derived from tumor growth dynamics based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The nontarget progression hazard was correlated to the first derivative of target lesion tumor size with respect to time. The PFS time was determined by the first occurring event, target lesion progression, or nontarget progression. The final joint model not only captured target lesion tumor growth dynamics but also predicted PFS well. A similar approach can potentially be used to predict PFS in future oncology studies. |
url |
https://doi.org/10.1002/psp4.12499 |
work_keys_str_mv |
AT jiajieyu anewmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics AT ninawang anewmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics AT mattskagedal anewmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics AT jiajieyu newmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics AT ninawang newmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics AT mattskagedal newmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics |
_version_ |
1724553557723578368 |